Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inovio Pharmaceuticals : confirms its Covid vaccine is safe in mid-stage trials

05/10/2021 | 09:43am EDT

Inovio Pharmaceuticals has confirmed its Covid-19 vaccine candidate is safe in a mid-stage clinical trial, as it produces immune responses against the virus in all tested age groups.

The trial, which included around 400 participants aged 18 years and older at 16 US sites, used a 2mg dose for the phase three segment of the trial. 

The drug, known as INO-4800, has had its trials funded by the US Department of Defence since last year.

The company’s shares were up 5.22 per cent on Friday afternoon at $6.85 on Nasdaq.

Read more: UK downgrades Covid-19 threat level

The US-based pharmaceutical firm plans to file preliminary mid-stage results with the U.S. Food and Drug Administration (FDA), Reuters reported.

The drug is also the only DNA-based vaccine that is stable at room temperature for more than a year, at 37 degrees for over a month and has a five-year shelf life.

“Our Phase two results validate our initial Covid-19 Phase one results in a larger population, which show that INO-4800 continues to be generally safe, well-tolerated and immunogenic in all studied age groups,” Inovio’s chief scientific officer, Dr Laurent M. Humeau said.

Phase one of the study showed the vaccine was well tolerated and induced high levels of antibody responses in roughly 95 per cent of study participants. 

Read more: Vaccine patents: When does free for all become a free-for-all?

The post Inovio confirms its Covid vaccine is safe in mid-stage trials appeared first on CityAM.

© City AM, source Newspaper

All news about INOVIO PHARMACEUTICALS, INC.
09/22INOVIO PHARMACEUTICALS : Gets Approval from Mexico Regulator for COVID-19 Vaccine Efficacy..
MT
09/22INOVIO PHARMACEUTICALS : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Tri..
PR
09/22INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID..
CI
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
MT
09/01INOVIO PHARMACEUTICALS : to Present at Upcoming Investor Conferences in September
PR
08/26INOVIO PHARMACEUTICALS : Receives Authorization From Brazil Regulator to Start Phase 3 Tri..
MT
08/26INOVIO PHARMACEUTICALS : Receives Authorization to Conduct Phase 3 Efficacy Trial of its C..
PR
08/26INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vac..
CI
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next month - C..
RE
08/09INOVIO PHARMACEUTICALS : focused on launching global COVID-19 vaccine trial next month - C..
RE
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,97x
Yield 2021 -
Capitalization 1 634 M 1 634 M -
Capi. / Sales 2021 347x
Capi. / Sales 2022 16,6x
Nbr of Employees 262
Free-Float 98,3%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,77 $
Average target price 13,22 $
Spread / Average Target 70,2%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-12.20%1 634
MODERNA, INC.291.35%165 027
LONZA GROUP AG26.86%57 923
IQVIA HOLDINGS INC.38.49%47 547
CELLTRION, INC.-25.49%31 003
SEAGEN INC.-7.21%29 566